{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T15:40:11Z","timestamp":1758901211410,"version":"3.44.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s12325-025-03322-4","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T10:54:12Z","timestamp":1754909652000},"page":"5088-5103","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Insights from Patients and Physicians About Use of Evolocumab for LDL-C Management"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9384-2255","authenticated-orcid":false,"given":"Eduard","family":"Sidelnikov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laney K.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amalia","family":"Debrosse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Okorozo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bethany","family":"Kalich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"key":"3322_CR1","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459\u201372.","journal-title":"Eur Heart J"},{"key":"3322_CR2","first-page":"e1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082\u2013143.","journal-title":"Circulation"},{"key":"3322_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111\u201388.","journal-title":"Eur Heart J"},{"key":"3322_CR4","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","volume":"80","author":"DM Lloyd-Jones","year":"2022","unstructured":"Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;80:1366\u2013418.","journal-title":"J Am Coll Cardiol"},{"key":"3322_CR5","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713\u201322.","journal-title":"N Engl J Med"},{"key":"3322_CR6","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","volume":"146","author":"ML O\u2019Donoghue","year":"2022","unstructured":"O\u2019Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation. 2022;146:1109\u201319.","journal-title":"Circulation"},{"key":"3322_CR7","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1001\/jamacardio.2021.1810","volume":"6","author":"CP Cannon","year":"2021","unstructured":"Cannon CP, de Lemos JA, Rosenson RS, et al. Use of lipid-lowering therapies over 2\u00a0years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiol. 2021;6:1060\u20138.","journal-title":"JAMA Cardiol"},{"key":"3322_CR8","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","volume":"28","author":"KK Ray","year":"2021","unstructured":"Ray KK, Molemans B, Schoonen WM, et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2021;28:1279\u201389.","journal-title":"Eur J Prev Cardiol"},{"key":"3322_CR9","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s40119-023-00334-5","volume":"12","author":"M Gupta","year":"2023","unstructured":"Gupta M, Wani RJ, Al Faraidy K, et al. Real-world insights into evolocumab use in patients with hyperlipidemia across five countries: analysis from the ZERBINI study. Cardiol Ther. 2023;12:703\u201322.","journal-title":"Cardiol Ther"},{"key":"3322_CR10","doi-asserted-by":"publisher","first-page":"190","DOI":"10.31083\/j.rcm2505190","volume":"25","author":"LA Leiter","year":"2024","unstructured":"Leiter LA, Hegele RA, Brown V, et al. Review of evolocumab for the reduction of LDL cholesterol and secondary prevention of atherosclerotic cardiovascular disease. Rev Cardiovasc Med. 2024;25:190 (Erratum in: Rev Cardiovasc Med. 2024;25:383).","journal-title":"Rev Cardiovasc Med"},{"key":"3322_CR11","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s40064-016-1892-3","volume":"5","author":"R Dent","year":"2016","unstructured":"Dent R, Joshi R, Stephen Djedjos C, et al. Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting. Springerplus. 2016;5:300.","journal-title":"Springerplus"},{"key":"3322_CR12","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1080\/14779072.2024.2398444","volume":"22","author":"S Sheth","year":"2024","unstructured":"Sheth S, Banach M, Banach PP. Closing the gap between guidelines and clinical practice for managing dyslipidemia: where are we now? Expert Rev Cardiovasc Ther. 2024;22:441\u201357.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"3322_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/acprof:oso\/9780199231881.001.0001","volume-title":"Health measurement scales: a practical guide to their development and use","author":"DL Streiner","year":"2008","unstructured":"Streiner DL, Norman GR. Health measurement scales: a practical guide to their development and use. 4th ed. Oxford, UK: Oxford University Press; 2008.","edition":"4"},{"key":"3322_CR14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1477-7525-2-12","volume":"2","author":"MJ Atkinson","year":"2004","unstructured":"Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12.","journal-title":"Health Qual Life Outcomes"},{"key":"3322_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1477-7525-7-36","volume":"7","author":"M Bharmal","year":"2009","unstructured":"Bharmal M, Payne K, Atkinson MJ, et al. Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes. 2009;7:36.","journal-title":"Health Qual Life Outcomes"},{"key":"3322_CR16","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.clinthera.2019.11.008","volume":"42","author":"JP Frias","year":"2020","unstructured":"Frias JP, Koren MJ, Loizeau V, et al. The SYDNEY Device Study: a multicenter, randomized, open-label usability study of a 2-mL alirocumab autoinjector device. Clin Ther. 2020;42:94-107.e5.","journal-title":"Clin Ther"},{"key":"3322_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1056\/NEJMp1211775","volume":"368","author":"MP Manary","year":"2013","unstructured":"Manary MP, Boulding W, Staelin R, et al. The patient experience and health outcomes. N Engl J Med. 2013;368:201\u20133.","journal-title":"N Engl J Med"},{"key":"3322_CR18","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.jpain.2010.07.009","volume":"12","author":"RH Dworkin","year":"2011","unstructured":"Dworkin RH, Jensen MP, Gould E, et al. Treatment satisfaction in osteoarthritis and chronic low back pain: the role of pain, physical and emotional functioning, sleep, and adverse events. J Pain. 2011;12:416\u201324.","journal-title":"J Pain"},{"key":"3322_CR19","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/j.hlc.2018.10.024","volume":"28","author":"R Mulchandani","year":"2019","unstructured":"Mulchandani R, Lyngdoh T, Chakraborty P, Kakkar AK. Satisfaction with statin treatment among adult coronary artery disease patients: an experience from a resource-constrained setting. Heart Lung Circ. 2019;28:1788\u201394.","journal-title":"Heart Lung Circ"},{"key":"3322_CR20","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2147\/PPA.S452849","volume":"18","author":"O Hoffmann","year":"2024","unstructured":"Hoffmann O, Paul F, Haase R, et al. Preferences, adherence, and satisfaction: three years of treatment experiences of people with multiple sclerosis. Patient Prefer Adher. 2024;18:455\u201366.","journal-title":"Patient Prefer Adher"},{"key":"3322_CR21","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/j.clinthera.2015.07.008","volume":"37","author":"EM Roth","year":"2015","unstructured":"Roth EM, Bujas-Bobanovic M, Louie MJ, et al. Patient and physician perspectives on mode of administration of the PCSK9 monoclonal antibody alirocumab, an injectable medication to lower LDL-C levels. Clin Ther. 2015;37:1945-54.e6.","journal-title":"Clin Ther"},{"key":"3322_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2217\/cer-2021-0105","volume":"10","author":"J Cos\u00edn-Sales","year":"2021","unstructured":"Cos\u00edn-Sales J, Rodr\u00edguez A, Gav\u00edn O, et al. Evaluating patients\u2019 satisfaction and preferences with a secondary prevention cardiovascular polypill: the AURORA study. J Comp Eff Res. 2021;10:17\u201327.","journal-title":"J Comp Eff Res"},{"key":"3322_CR23","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.cjco.2021.06.015","volume":"3","author":"S Salmasi","year":"2021","unstructured":"Salmasi S, Loewen P, Andrade JG, et al. Satisfaction with oral anticoagulants among patients with atrial fibrillation: a prospective observational study. CJC Open. 2021;3:1347\u201356.","journal-title":"CJC Open"},{"key":"3322_CR24","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1080\/03007995.2018.1532885","volume":"35","author":"MH Tai","year":"2019","unstructured":"Tai MH, Shepherd J, Bailey H, et al. Real-world treatment patterns of PCSK9 inhibitors among patients with dyslipidemia in Germany, Spain, and the United Kingdom. Curr Med Res Opin. 2019;35:829\u201335.","journal-title":"Curr Med Res Opin"},{"key":"3322_CR25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s40256-017-0246-z","volume":"18","author":"PB Rane","year":"2018","unstructured":"Rane PB, Patel J, Harrison DJ, et al. Patient characteristics and real-world treatment patterns among early users of PCSK9 inhibitors. Am J Cardiovasc Drugs. 2018;18:103\u20138.","journal-title":"Am J Cardiovasc Drugs"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03322-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03322-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03322-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T15:09:14Z","timestamp":1758899354000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03322-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["3322"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03322-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"assertion":[{"value":"20 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Eduard Sidelnikov is an employee of Amgen (Europe) GmbH and holds stock in Amgen Inc. Laney K. Jones is an employee of Amgen and holds stock in Amgen Inc. Amalia Debrosse is an employee of Avalere Health that conducted this research study sponsored by Amgen Inc.\u00a0Peter Okorozo was an employee of Avalere Health that conducted this research study sponsored by Amgen Inc. Bethany Kalich is an employee of Amgen and holds stock in Amgen Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted by Avalere Health (London, UK), a contract research organization, in accordance with the ethical principles specified in the Declaration of Helsinki and the requirements of the European Union General Data Protection Regulation. All participants provided electronic informed consent to participate in the survey. All personal information of all participants was de-identified to protect confidentiality. The survey was double-blind; participants did not know who the sponsor was, and the sponsor did not have access to any individual information about participants. On this basis, an institutional review board (IRB) exemption was granted by the central WCG Internal Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}